GlobeNewswire EN Nachrichten :: Artikel

08.11.25 - 23:15

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (GlobeNewswire EN)

CAMBRIDGE, Mass., Nov. 08, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented positive clinical data from a pooled analysis of all patients who received a 50 milligram (mg) dose of lonvo-z in the company's ongoing Phase 1/2 clinical trial in patients with hereditary angioedema (HAE). These results were shared in an oral presentation today at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, Florida....

08.11.25 - 20:33	Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 (GlobeNewswire EN)
	Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life...

08.11.25 - 17:48	Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China (GlobeNewswire EN)
	Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile...

08.11.25 - 17:33	Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases (GlobeNewswire EN)
	Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to...

08.11.25 - 17:27	Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy (GlobeNewswire EN)
	MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research...

08.11.25 - 17:03

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 (GlobeNewswire EN)

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today presented two posters for JADE101, its investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2025....

08.11.25 - 16:51	Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet (GlobeNewswire EN)
	Proof-of-concept trials confirm robust anti-clotting effects for Regeneron's two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement...

08.11.25 - 16:45	Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations (GlobeNewswire EN)
	- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated:...

08.11.25 - 16:00	CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering (GlobeNewswire EN)
	-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025-...

08.11.25 - 09:21	Novo Nordisk will not increase its proposal to acquire Metsera, Inc. (GlobeNewswire EN)
	Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera....

08.11.25 - 07:12	Fangzhou Awarded “Golden Bull Award” for Leadership in AI-Powered Chronic Disease Management (GlobeNewswire EN)
	Fangzhou was recognized with the “Social Responsibility Golden Bull Award”....

08.11.25 - 03:48	Canacol Energy Ltd Provides Information on Arbitration Process (GlobeNewswire EN)
	CALGARY, Alberta, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. (“Canacol” or the “Company”) announces that it has been notified of the decision issued in the domestic arbitration proceedings initiated by VP Ingenergía S.A.S. E.S.P. before the Arbitration and Conciliation Center of the Bogotá Chamber of Commerce....

08.11.25 - 03:06	Ascot Announces Launch of C$0.01 Rights Offering (GlobeNewswire EN)
	VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascot Resources Ltd. (TSXV: AOT.H; OTCQB: AOTVF) (“Ascot” or the “Company”) announces it is undertaking a rights offering to raise gross proceeds of up to C$14,871,517 (the “Rights Offering”)....

08.11.25 - 02:09	South Star Announces Upsize of Non-Brokered Private Placement (GlobeNewswire EN)
	- NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES -...

08.11.25 - 01:24	Integral Metals Announces Closing of Private Placement Offerings (GlobeNewswire EN)
	NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...

08.11.25 - 01:03	CORRECTION – Cheetah Net Supply Chain Service Inc. Announces Third Quarter 2025 Results (GlobeNewswire EN)
	IRVINE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cheetah Net Supply Chain Service Inc. (Nasdaq CM: CTNT), please note that in the second paragraph, corrections have been made to operating loss, interest income and percentage figures. The corrected release follows:...

08.11.25 - 00:48	NEXTGEN DIGITAL CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT OF UNITS (GlobeNewswire EN)
	– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – – NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES –...

08.11.25 - 00:30	Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy (GlobeNewswire EN)
	Vera Therapeutics Submits BLA to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgAN...

08.11.25 - 00:24	Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Decrease In October 2025 of 0.8% Compared to 2024 (GlobeNewswire EN)
	GUADALAJARA, Mexico, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for October 2025, compared with October 2024....

08.11.25 - 00:12	Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire EN)
	– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –...

>weitere News anzeigen...